Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Blood Biomarkers to Improve the Diagnosis of Cystic Fibrosis Pulmonary Exacerbations
FY 2020-21
Summary
Pulmonary exacerbations (PEx) are common events for cystic fibrosis (CF) patients that cause difficulty breathing, worsening cough and mucus production due to uncontrolled inflammation and infection. Timely treatment of PEx with antibiotics is important to minimize irreversible airway damage. Currently, CF patients have quarterly routine appointments to assess any change in symptoms and lung function, to ensure that they can be quickly diagnosed and treated for PEx. When patients experience increased respiratory symptoms and a drop in lung function, the clinical decision to treat with antibiotics is clear. However, deciding whether to treat with antibiotics is unclear when only an increase in symptoms or a decrease in lung function is seen, weighing the consequences of antibiotic overuse with permanent loss of lung function. Developing a blood test for PEx could help improve diagnosis and treatment of PEx. Our group has found that C-reactive protein (CRP) and calprotectin could be used in a blood test to differentiate PEx from stable status. We hypothesize that a blood test for CRP and calprotectin will help identify patients that will do poorly without antibiotics when showing only a change in symptoms or a decline in lung function. My specific objectives are to compare the respiratory outcomes of patients with versus without high levels of CRP and calprotectin. I will use blood samples from CF patients who experienced either an increase in respiratory symptoms or a decline in lung function and evaluate if the blood test can predict worse respiratory outcomes at clinical follow up without antibiotic treatment. If this blood test is found to be useful, it will improve outcomes for many CF patients allowing PEx to be better diagnosed and treated.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
449356
Name
Potter Naomi M
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Blood Biomarkers to Improve the Diagnosis of Cystic Fibrosis Pulmonary Exacerbations
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biomarkers; Cystic Fibrosis; Diagnosis; Exacerbations; Inflammation
Abstract
Pulmonary exacerbations (PEx) are common events for cystic fibrosis (CF) patients that cause difficulty breathing, worsening cough and mucus production due to uncontrolled inflammation and infection. Timely treatment of PEx with antibiotics is important to minimize irreversible airway damage. Currently, CF patients have quarterly routine appointments to assess any change in symptoms and lung function, to ensure that they can be quickly diagnosed and treated for PEx. When patients experience increased respiratory symptoms and a drop in lung function, the clinical decision to treat with antibiotics is clear. However, deciding whether to treat with antibiotics is unclear when only an increase in symptoms or a decrease in lung function is seen, weighing the consequences of antibiotic overuse with permanent loss of lung function. Developing a blood test for PEx could help improve diagnosis and treatment of PEx. Our group has found that C-reactive protein (CRP) and calprotectin could be used in a blood test to differentiate PEx from stable status. We hypothesize that a blood test for CRP and calprotectin will help identify patients that will do poorly without antibiotics when showing only a change in symptoms or a decline in lung function. My specific objectives are to compare the respiratory outcomes of patients with versus without high levels of CRP and calprotectin. I will use blood samples from CF patients who experienced either an increase in respiratory symptoms or a decline in lung function and evaluate if the blood test can predict worse respiratory outcomes at clinical follow up without antibiotic treatment. If this blood test is found to be useful, it will improve outcomes for many CF patients allowing PEx to be better diagnosed and treated.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Potter, Naomi M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~